[The concept of biologic progression in metastatic cancer of the prostate hormonally treated].
A total of 110 patients with hormone-treated metastatic prostate cancer were monitored quarterly with serial PSA determinations. At the first control, 6 patients had progressed clinically, 5 of which had decreased PSA ranging between 9-77%. After a period of response, 69 patients progressed clinically, of which 1 showed no elevation of PSA levels, 14 showed progression concurrent with PSA increase, and 54 showed a period of gradual elevation of PSA over a range of 2-31 months. The probability of biological progression when the first rise occurred ranged between 72-96%, which after a second increase ranged between 92-100%, and all patients with three consecutive increases progressed clinically.
Morote
J
J
Servicio de Urología, Hospital General Universitario Vall d'Hebron, Barcelona.
Lorente
J A
JA
Vallejo
C
C
Encabo
G
G
López-Pacios
M A
MA
De Torres
J A
JA
Soler Roselló
A
A
D000726:Androgen Antagonists / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D012074:Remission Induction
D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen